Table 6.
Prior Studies Evaluating Survival as a Function of EGFR
| Author | Population | Patients | Median OS EGFR(+) | Median OS EGFR (−) | p value |
|---|---|---|---|---|---|
| Kosaka et al | Surgically resected patients progressing after gefitinib | 91 | 86% 3 year survival | 91% 3 year survival | 0.993 |
| Shigematsu et al | Patients with NSCLC | 617 | 50 mo* | 60 mo* | 0.5 |
| Tokumo et al | Surgically resected NSCLC | 120 | 25.1 mo | 14 mo | 0.153 |
| Eberhard et al | TRIBUTE substudy | 274 | ND | 10 mo | <0.001 |
| Sasaki et al | Surgically resected NSCLC | 95 | ND* | ND* | 0.1824 |
| Sequist et al | All EGFR referrals | 278 | 37.2 months | 19.2 months | 0.001 |
| Marks et al | AdenoCA, resected at MSKCC | 296 | ND | ND | 0.18 |
| Johnson et al | Stage IV AdenoCA at MSKCC | 1036 | 33.7 months | 20.7 months | <0.001 |
ND = Not defined
*
Median estimates were not reported and therefore were9 approximated from Kaplan-Meier Curve